MDM2 and breast cancer: Collectively, our data demonstrate that circNUDT21 acts as an oncogenic circRNA in BC progression through the miR-16-1-3p/MDM2/p53 axis, and may serve as a promising diagnostic marker and therapeutic target for BC.